A
Alessandro Antonelli
Researcher at University of Pisa
Publications - 22
Citations - 4356
Alessandro Antonelli is an academic researcher from University of Pisa. The author has contributed to research in topics: Hepatitis C virus & Thyroid. The author has an hindex of 21, co-authored 22 publications receiving 3627 citations. Previous affiliations of Alessandro Antonelli include University of Modena and Reggio Emilia.
Papers
More filters
Journal ArticleDOI
Autoimmune thyroid disorders.
Alessandro Antonelli,Silvia Martina Ferrari,Alda Corrado,Andrea Di Domenicantonio,Poupak Fallahi +4 more
TL;DR: E Epidemiological data suggest that AITD patients should be accurately monitored for thyroid dysfunctions, the appearance of thyroid nodules, and other autoimmune disorders.
Journal ArticleDOI
Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients.
Clodoveo Ferri,Marco Sebastiani,Dilia Giuggioli,M Cazzato,Giovanni Longombardo,Alessandro Antonelli,R Puccini,Claudio Michelassi,Anna Linda Zignego +8 more
TL;DR: Careful patient monitoring is recommended for a timely diagnosis of life-threatening Mixed cryoglobulinemia complications, mainly nephropathy, widespread vasculitis, and B-cell lymphoma or other malignancies.
Journal ArticleDOI
Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
Alessandro Antonelli,Silvia Martina Ferrari,Dilia Giuggioli,Ele Ferrannini,Clodoveo Ferri,Poupak Fallahi +5 more
TL;DR: Determination of high level of CXCL10 in peripheral fluids is therefore a marker of host immune response, especially T helper (Th)1 orientated T-cells, therefore creating an amplification feedback loop, and perpetuating the autoimmune process.
Journal ArticleDOI
Teprotumumab for Thyroid-Associated Ophthalmopathy
Terry J. Smith,George J. Kahaly,Daniel G. Ezra,James C. Fleming,Roger A. Dailey,Rosa A. Tang,Gerald J. Harris,Alessandro Antonelli,Mario Salvi,Robert A. Goldberg,James W Gigantelli,Steven M. Couch,Erin M. Shriver,Brent Hayek,Eric M. Hink,Richard M. Woodward,Kathleen Gabriel,Guido Magni,Raymond S. Douglas +18 more
TL;DR: In patients with active ophthalmopathy, teprotumumab was more effective than placebo in reducing proptosis and the Clinical Activity Score, and the only drug‐related adverse event was hyperglycemia in patients with diabetes.
Journal ArticleDOI
Teprotumumab for the Treatment of Active Thyroid Eye Disease
Raymond S Douglas,George J. Kahaly,Amy Patel,Saba Sile,Elizabeth H.Z. Thompson,Renee Perdok,James C. Fleming,Brian T. Fowler,Claudio Marcocci,Michele Marinò,Alessandro Antonelli,Roger A. Dailey,Gerald J. Harris,Anja Eckstein,Jade S. Schiffman,Rosa A. Tang,Christine C. Nelson,Mario Salvi,Sara T. Wester,Jeffrey W. Sherman,Thomas Vescio,Robert J. Holt,Terry J. Smith +22 more
TL;DR: Among patients with active thyroid eye disease, teprotumumab resulted in better outcomes with respect to proptosis, Clinical Activity Score, diplopia, and quality of life than placebo; serious adverse events were uncommon.